Edmundo Muniz, M.D., Ph.D.
President and Chief Executive Officer

Dr. Muniz brings over 15 years of drug development experience in oncology, Cardiovascular, and infectious disease. Prior to joining Tigris, Dr. Muniz was Vice President for Lilly Research Laboratories Global Oncology Platform at Eli Lilly and Company. At Lilly, Dr. Muniz was responsible for Phase II, III and IV clinical trials for oncology compounds worldwide and for Global Marketing Pre-launch.

Under Dr. Muniz's leadership, Lilly Oncology achieved 9 major oncology submissions worldwide, with all 9 of those already having gained approval in the US, Europe and Japan. Such projects include Dr. Muniz's extensive involvement in the development of approved oncology therapeutics Alimta® and Gemzar®. Additionally, Dr. Muniz led the launch of Lilly Oncology on Canvas: Expressions of a Woman's Cancer Journey, an international art exhibition that displays works from over 400 cancer survivors, family members, care providers and friends. Prior to joining Eli Lilly, Dr. Muniz completed a PhD in Epidemiology and International Health at the University of Michigan and later completed a residency in Preventive Medicine and a Fellowship in Epidemic Intelligence with the Centers for Disease Control and Prevention (CDC) in Atlanta.

Anne White
Chief Operating Officer, Vice President, Clinical Operations

Ms. White brings 15 years of drug development experience to Tigris Pharmaceuticals. Prior to joining Tigris, Ms. White was the Chief Operating Officer for the Global Oncology Platform at Eli Lilly and Company, where she received Eli Lilly's Women's Network 2005 Leadership Award. Ms. White's career at Eli Lilly and Company has spanned clinical development operations leadership in oncology, infectious diseases, and neuroscience. In her most recent position at Lilly Oncology, Ms. White was responsible for the clinical development of three oncology products, both pre- and post-registration. During Ms. White's tenure, Lilly Oncology submitted 9 major applications in the US, EU and Japan and initiated over 100 clinical studies globally.

Binh Nguyen, M.D., Ph.D.
Vice President of Clinical Development and Chief Medical Officer

Dr. Nguyen possesses over 10 years of experience in oncology clinical drug development and regulatory affairs. Prior to joining Tigris, Dr. Nguyen served as Executive Director of the Oncology Platform Team and of the Pharmacogenomic Program for Eli Lilly and Company. In this role, Dr. Nguyen was responsible for the overall clinical development plan with correlated translational research of numerous early- and late-stage molecules. He managed interactions with regulatory authorities in the US, Europe, and Japan, and has successfully led two defenses at the Oncologic Drug Advisory Committee (ODAC) of the US Food and Drug Administration (FDA). He has achieved successful global approvals for two drugs in six indications (mesothelioma, 1st line and 2nd line NSCLC, pancreatic, bladder, breast and ovarian cancer).

Prior to his work with Eli Lilly, Dr. Nguyen completed his medical oncology fellowship at the National Cancer Institute and was a Clinical Fellow at the Cancer Therapy Evaluation Program (CTEP), where he was responsible for the clinical development plan of investigational drugs. Dr. Nguyen was also a fellow at the Center for Drug Evaluation and Research (CDER) at the Division of Pulmonary and Oncology Drug Products of the FDA, where he was responsible for reviewing Investigational New Drug (IND) and New Drug Application (NDA) filings.

Leslie Carter, Pharm.D., BS Pharmacy
Vice President, Regulatory and CMC

Dr. Carter brings 20 years of pharmaceutical industrial experience to Tigris Pharmaceuticals. Prior to joining Tigris, Dr. Carter served as the Director of Global Operations in the Global Regulatory Affairs Department at Eli Lilly and Company. She was responsible for overseeing development and maintenance of global and U.S. labeling and submissions for all products. Dr. Carter also has experience from other pharmaceutical companies including Procter & Gamble Pharmaceuticals and GSK.

Dr. Carter has an extensive background in pharmaceutical drug development. She has accumulated 10 years of regulatory experience with compounds in all phases of the drug development lifecycle and across multiple therapeutic areas including Women's Health, cardiovascular, immunologic and infectious diseases. She also has experience with formulation development, clinical research oversight, and drug information and marketed product support. In her previous roles, she has been an active member on PhRMA Working Groups and led several successful regulatory filings with FDA and other regulatory agencies.